Skip to main content

Wheezing

1
Pipeline Programs
5
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 3 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
1
Soy isoflavonePhase 2
Physical Sciences
Physical SciencesMA - Andover
1 program
Lung function monitoring equipment at home - 2 weeksN/A1 trial
Active Trials
NCT05447832Unknown100Est. Mar 2024
Regeneron
RegeneronTARRYTOWN, NY
1 program
DupilumabPHASE_3Monoclonal Antibody
Verona Pharma
Verona PharmaUK - London
1 program
MontelukastPHASE_41 trial
Active Trials
NCT00775697Unknown40Est. Dec 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Verona PharmaMontelukast
Physical SciencesLung function monitoring equipment at home - 2 weeks

Clinical Trials (2)

Total enrollment: 140 patients across 2 trials

Montelukast in Children With Wheezing

Start: Sep 2009Est. completion: Dec 201440 patients
Phase 4Unknown
NCT05447832Physical SciencesLung function monitoring equipment at home - 2 weeks

Remote Monitoring in Preschool Wheeze

Start: Aug 2022Est. completion: Mar 2024100 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.